Advanced search
Start date

Electronic controlled carrier for somatic stem cells for therapeutic use


Recent progress in the area of studies on the use of stem cells for therapeutic purposes, both in veterinary and human medicine, opens the prospect of a growing potential in the medium and long term. However, the area still lacks the development of products that enable its application in large scale. This project aims to analyze the technical-scientific feasibility of developing a carrier of stem cells for therapeutic use. Operating for more than a decade in reproductive biotechnology market, the WTA has demonstrated since it´s foundation, a high capacity for innovation. The company is responsible for the development of various equipment for the logistics of biological material of animal origin, having many patents generated as result of its research and development (R & D) activities. This project will be developed along the lines of WTA´s Oocyte Carrier TO 16i®, whose technology includes the use of temperature sensors and high-precision batteries that allow a range of transport that can reach 24 hours. Thus, the studies will have to analyze the feasibility of developing a device with modular compartments that allow their future adaptation to other possible technologies, and are intended for principle, allocation and transportation of transfer bags containing stem cells for use therapeutic with a capacity of 300 ml each. The entire development of the project will be based on the therapeutic use of animal cells, aiming at their future adaptation and use in human clinical field, which is why the project has the support and partnership of the Blood Center of Ribeirão Preto and Cell Therapy Center - CEPID, attached to the Faculty of Medicine Ribeirão Preto, University of São Paulo (FMRP-USP). This partnership will allow the adaptations to be made according to the rules dictated by Resolution RDC No. 20 of April 10, 2014, which provides for the health regulations for the transport of biological material; RDC Resolution No. 34, dated June 11, 2014 which provides for Good Practice in the Cycle of Blood and RDC No. 56 of December 16, 2010 that hotdog on the operation of laboratories hematopoietic progenitor cells (ANVISA, 2014; ANVISA, 2014 , ANVISA, 2010).The methodology will use derived multipotent mesenchymal cells of somatic primary bovine tissues, obtained from bone marrow, adipose tissue and also multipotent mesenchymal cells derived from human umbilical cord (after approval of the local zip code and signature of donor TBI).These cells will be used to conduct tests whose purpose is to verify the feasibility, survival, maintenance of immunophenotypic characteristics, differentiation potential and chromosome stability of biological material, post-transport. Assessments will be conducted after 12, 18 and 24 hours in temperatures defined in current legislation on transport of human biological material, previously cited. (AU)

Articles published in Agência FAPESP Newsletter about the research grant:
Articles published in other media outlets (0 total):
More itemsLess items

Please report errors in scientific publications list using this form.